Skip to main content

Table 1 (Abstract O5). Clinical data

From: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Pt

Age

Disease

Prior Tx

BATS (x 109)

TTP (mo)

OS (mo)

Comments

IT20087

58

Mets to liver

Folfirinox

47

6 mo

Died 13.6 mo

Progressed after Immunotherapy

IT20091

63

T3 N1Mets to liver. S/P Whipple

5FU, Leu/5FU Folfirinox

9 79

4.8 mo

Died 31 mo

Folfirinox induced CR after IT and responded a 2nd time to Folfirinox

IT20092

64

T2b Abd Nodes, S/P Whipple

Gemzar, 5FU, radiation

36

7 mo

Died 14.5 mo

Slowly progress with chronic diarrhea

IT20102

56

T4, Mets to liver, lungs

Folfirinox

74

6.5 mo

Alive 24.9 mo

Progressed after 6.5 mo

IT20104

51

T4, Abd Node

FOLFOX, X eloda

72

2.2 mo

Alive 23.3 mo

Chemo Induced CR after IT; On Xeloda